Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Sotyktu (deucravacitinib) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Deucravacitinib significantly increased the achievement of PASI 75 compared to placebo (RR 5.7; 95% CI 4.32-7.53; P<0.001) and improved ss-PGA 0/1 (RR 3.86; 95% CI 3.02-4.94; P<0.001) and DLQI 0/1 (RR 3.89; 95% CI 2.89-5.22; P<0.001).
• Compared to apremilast, deucravacitinib (at various dosages) showed superior efficacy in PASI 75, sPGA 0/1, PASI 90, PASI 100, and DLQI 0/1 at week 16.
• Tofacitinib (15 mg BID) had a higher probability of achieving PASI 75 compared to deucravacitinib (12 mg QD), with similar trends observed in PGA response rates.
• The incidence of serious adverse events (SAEs) was similar between deucravacitinib and placebo groups, and deucravacitinib was generally well-tolerated with a low and balanced incidence of adverse events (AEs), SAEs, and AE-related treatment discontinuations across groups.
• Deucravacitinib did not lead to a higher incidence of AEs than apremilast (30 mg BID), and among JAK inhibitors, deucravacitinib (6 mg BID and 12 mg QD) was non-inferior in safety compared to placebo, with tofacitinib (2 mg BID) ranked highest for safety.
• The reviewed studies primarily focus on adult patients with moderate-to-severe psoriasis, predominantly male (70.2%), with a mean age of 45.4 years, and a significant proportion had a history of scalp psoriasis; deucravacitinib significantly decreased disease severity and improved quality of life in this population without a concerning increase in the incidence of serious adverse events.